Karyopharm Therapeutics Inc.
KPTI · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.02 | 0.02 | -0.08 | 0.10 |
| FCF Yield | -154.93% | -93.81% | -53.77% | -23.36% |
| EV / EBITDA | -5.55 | -1.89 | -2.31 | -4.88 |
| Quality | ||||
| ROIC | -123.21% | -73.11% | -47.82% | -41.69% |
| Gross Margin | 95.86% | 96.62% | 96.68% | 98.38% |
| Cash Conversion Ratio | 1.67 | 0.65 | 0.90 | 0.86 |
| Growth | ||||
| Revenue 3-Year CAGR | -2.58% | -11.38% | 13.27% | 72.48% |
| Free Cash Flow Growth | -37.64% | 38.05% | -32.66% | 29.65% |
| Safety | ||||
| Net Debt / EBITDA | -3.42 | -1.05 | -0.32 | 0.10 |
| Interest Coverage | -3.19 | -5.44 | -5.69 | -3.77 |
| Efficiency | ||||
| Inventory Turnover | 1.27 | 1.62 | 1.23 | 0.83 |
| Cash Conversion Cycle | 54.96 | 61.48 | 211.01 | 307.68 |